<inglise> COMMISSION REGULATION (EC) No 649/98 of 23 March 1998 amending the Annex to Council Regulation (EEC) No 2309/93 (Text with EEA relevance) </inglise>
<eesti> KOMISJONI M&Auml;&Auml;RUS (E&Uuml;) nr 649/98, millega muudetakse n&otilde;ukogu m&auml;&auml;ruse (EM&Uuml;) nr 2309/93 lisa 23. m&auml;rts 1998 (EMPs kohaldatav tekst) </eesti>
<inglise> THE COMMISSION OF THE EUROPEAN COMMUNITIES, </inglise>
<eesti> EUROOPA &Uuml;HENDUSTE KOMISJON, </eesti>
<inglise> Having regard to the Treaty establishing the European Community, </inglise>
<eesti> v&otilde;ttes arvesse Euroopa &Uuml;henduse asutamislepingut, </eesti>
<inglise> Having regard to Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products (1), and in particular Article 3(5) thereof, </inglise>
<eesti> v&otilde;ttes arvesse n&otilde;ukogu 22. juuli 1993. aasta m&auml;&auml;rust (EM&Uuml;) nr 2309/93, milles s&auml;testatakse &uuml;henduse kord inimtervishoius ja veterinaarias kasutatavate ravimite lubade andmise ja j&auml;relevalve kohta ning millega asutatakse Euroopa ravimihindamisamet, eriti selle artikli 3 l&otilde;iget 5, </eesti>
<inglise> Whereas for the purposes of animal health protection and given the specific nature of the market in veterinary medicinal products, encouragement should be given to pharmaceutical companies so that new and/or innovative medicinal products in the veterinary field are placed on the market as soon as possible; </inglise>
<eesti> ning arvestades, et: loomade tervise kaitseks ja veterinaarravimite turu eriiseloomu arvestades tuleks julgustada ravimitootjaid v&otilde;imalikult kiiresti paigutama turule uusi ja/v&otilde;i uuenduslikke veterinaartooteid; </eesti>
<inglise> Whereas pharmaceutical companies are bound by essential requirements for the development of medicinal products relating to, inter alia, clinical and toxicological studies; whereas these essential requirements vary according to whether the medicinal product is intended for domestic animals, animals producing food for human consumption or both categories of animal; </inglise>
<eesti> ravimitootjad on seotud ravimite arendamise p&otilde;hin&otilde;uetega, mis muu hulgas k&auml;sitlevad kliinilisi ja toksikoloogilisi uuringuid; need p&otilde;hin&otilde;uded varieeruvad vastavalt sellele, kas ravim on m&otilde;eldud koduloomadele, inimtarbimiseks kasvatatavatele loomadele v&otilde;i m&otilde;lema liigi loomadele; </eesti>
<inglise> Whereas new and innovative veterinary medicinal products should be the subject of coherent and effective supervision by way of pharmacovigilance; whereas it is therefore preferable to entrust the supervision of a particular medicinal product to a single national or Community authority, regardless of its indications and target species; </inglise>
<eesti> uusi ja uuenduslikke veterinaarravimeid tuleks j&auml;rjekindlalt ja t&otilde;husalt hoida ravimiohutuse j&auml;relevalve all; seet&otilde;ttu on soovitatav usaldada konkreetse ravimi j&auml;relevalve &uuml;hele siseriiklikule v&otilde;i &uuml;henduse asutusele, hoolimata selle n&auml;idustustest v&otilde;i sihtliigist; </eesti>
<inglise> Whereas it is also necessary to improve the transparency of and ease of access to the market in veterinary medicinal products by offering pharmaceutical companies the possibility, for a given new and/or innovative medicinal product, of a single type of national or Community authorisation whatever the target species for that product; </inglise>
<eesti> samuti on vaja parandada veterinaarravimite turu l&auml;bipaistvust ja ligip&auml;&auml;setavust, andes ravimitootjatele v&otilde;imaluse saada konkreetse uue ja/v&otilde;i uuendusliku ravimi puhul &uuml;ks siseriiklik v&otilde;i &uuml;henduse luba olenemata toote sihtliigist; </eesti>
<inglise> Whereas therefore it must be possible for the European Agency for the Evaluation of Medicinal Products to carry out an evaluation, at the request of a company, of any veterinary medicinal product containing a new active substance which, on the date of entry into force of this Regulation, was not authorised by any Member State for use in animals; </inglise>
<eesti> see&otilde;ttu peab Euroopa Ravimihindamisametil olema v&otilde;imalik hinnata ettev&otilde;tja taotlusel iga veterinaarravimit, mis sisaldab ainet, mida k&auml;esoleva m&auml;&auml;ruse j&otilde;ustumise kuup&auml;eval ei olnud &uuml;heski liikmesriigis lubatud kasutada loomade raviks; </eesti>
<inglise> Whereas the measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Veterinary Medicinal Products, </inglise>
<eesti> k&auml;esolevas m&auml;&auml;ruses s&auml;testatud meetmed on koosk&otilde;las veterinaarravimite alalise komitee arvamusega, </eesti>
<inglise> HAS ADOPTED THIS REGULATION: </inglise>
<eesti> ON VASTU V&Otilde;TNUD K&Auml;ESOLEVA M&Auml;&Auml;RUSE. </eesti>
<inglise> Article 1 </inglise>
<eesti> Artikkel 1 </eesti>
<inglise> In the Annex to Regulation (EEC) No 2309/93, Part B, the last indent shall be replaced by the following text: </inglise>
<eesti> M&auml;&auml;ruse (EM&Uuml;) nr 2309/93 lisa B osa viimane taane asendatakse j&auml;rgmise tekstiga: </eesti>
<inglise> 'Veterinary medicinal products containing a new active substance which, on the date of entry into force of this Regulation, was not authorised by any Member State for use in animals'. </inglise>
<eesti> "Veterinaarravimid, mis sisaldavad uut aktiivainet, mida k&auml;esoleva m&auml;&auml;ruse j&otilde;ustumise kuup&auml;eval ei olnud &uuml;heski liikmesriigis lubatud kasutada loomade raviks." </eesti>
<inglise> Article 2 </inglise>
<eesti> Artikkel 2 </eesti>
<inglise> This Regulation shall enter into force on the day following its publication in the Official Journal of the European Communities. </inglise>
<eesti> K&auml;esolev m&auml;&auml;rus j&otilde;ustub j&auml;rgmisel p&auml;eval p&auml;rast selle avaldamist Euroopa &Uuml;henduste Teatajas. </eesti>
<inglise> This Regulation shall be binding in its entirety and directly applicable in all Member States. </inglise>
<eesti> K&auml;esolev m&auml;&auml;rus on tervikuna siduv ja vahetult kohaldatav k&otilde;ikides liikmesriikides. </eesti>
<inglise> Done at Brussels, 23 March 1998. </inglise>
<eesti> Br&uuml;ssel, 23. m&auml;rts 1998 </eesti>
<inglise> For the Commission Martin BANGEMANN Member of the Commission </inglise>
<eesti> Komisjoni nimel komisjoni liige Martin BANGEMANN </eesti>
<inglise> (1) OJ L 214, 24.8.1993, p. 1. </inglise>
<eesti> (1) E&Uuml;T L 214, 24.08.1993, lk 1. </eesti>
 